On Tuesday, C4 Therapeutics Inc (NASDAQ: CCCC) opened higher 8.45% from the last session, before settling in for the closing price of $2.13. Price fluctuations for CCCC have ranged from $1.09 to $4.07 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -8.92% over the last five years. Company’s average yearly earnings per share was noted 7.51% at the time writing. With a float of $78.36 million, this company’s outstanding shares have now reached $96.91 million.
C4 Therapeutics Inc (CCCC) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of C4 Therapeutics Inc is 19.14%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.49 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.69% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Check out the current performance indicators for C4 Therapeutics Inc (CCCC). In the past quarter, the stock posted a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.22 in one year’s time.
